ArticleBlood research2023

Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study.

Ja Min Byun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.